Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : SNY crawled time : 16:20 save search
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
Published: 2024-03-10 (Crawled : 16:20) - globenewswire.com
SNY | News | $46.135 1.64% 270K
|
Health Technology
| Email alert
Add to watchlist
MLTX | $42.515 0.63% 45K
|
| Email alert
Add to watchlist
SNYNF | News | $92.7 600K
|
Health Technology
| Email alert
Add to watchlist
nanobody day active
Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria
Published: 2024-02-24 (Crawled : 16:20) - globenewswire.com
SNY | News | $46.135 1.64% 270K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 600K
|
Health Technology
| Email alert
Add to watchlist
disease urticaria results
Calliditas Therapeutics appoints Maria Törnsén as President North America
Published: 2024-01-07 (Crawled : 16:20) - prnewswire.com
SNY | News | $46.135 1.64% 270K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 600K
|
Health Technology
| Email alert
Add to watchlist
CALT | News | $17.65 1.1K
|
Health Technology
| Email alert
Add to watchlist
america therapeutics
Sanofi and Minapharm Sign an Exclusive Agreement for Localizing the manufacture of Clexane®
Published: 2023-12-10 (Crawled : 16:20) - prnewswire.com
SNY | News | $46.135 1.64% 270K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 600K
|
Health Technology
| Email alert
Add to watchlist
clexane agreement sanofi
MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis
Published: 2023-11-05 (Crawled : 16:20) - globenewswire.com
SNY | News | $46.135 1.64% 270K
|
Health Technology
| Email alert
Add to watchlist
MLTX | $42.515 0.63% 45K
|
| Email alert
Add to watchlist
SNYNF | News | $92.7 600K
|
Health Technology
| Email alert
Add to watchlist
nanobody active results phase 2
Libtayo® (cemiplimab) Neoadjuvant Treatment Demonstrates Encouraging Event-Free Survival in Patients with Resectable Cutaneous Squamous Cell Carcinoma (CSCC)
Published: 2023-10-21 (Crawled : 16:20) - globenewswire.com
SNY | News | $46.135 1.64% 270K
|
Health Technology
| Email alert
Add to watchlist
REGN | $901.745 0.87% 87K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 600K
|
Health Technology
| Email alert
Add to watchlist
libtayo cell treatment
MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa
Published: 2023-10-15 (Crawled : 16:20) - globenewswire.com
SNY | News | $46.135 1.64% 270K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 600K
|
Health Technology
| Email alert
Add to watchlist
MLTX | $42.515 0.63% 45K
|
| Email alert
Add to watchlist
nanobody solution
Swedish Orphan Biovitrum AB: Late-breaking efanesoctocog alfa data presented at ISTH demonstrates highly effective bleed protection in children with severe haemophilia A with once-weekly dosing
Published: 2023-06-25 (Crawled : 16:20) - prnewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
| Email alert
Add to watchlist
CTIC | $9.09 0.05% 11M
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.135 1.64% 270K
|
Health Technology
| Email alert
Add to watchlist
children haemophilia
MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa
Published: 2023-06-25 (Crawled : 16:20) - globenewswire.com
MLTX | $42.515 0.63% 45K
|
| Email alert
Add to watchlist
SNYNF | News | $92.7 600K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.135 1.64% 270K
|
Health Technology
| Email alert
Add to watchlist
nanobody positive results milestone phase 2
Press Release: ALTUVIIIO late-breaking data at ISTH demonstrates highly effective bleed protection in children with severe hemophilia A with once-weekly dosing
Published: 2023-06-25 (Crawled : 16:20) - globenewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.135 1.64% 270K
|
Health Technology
| Email alert
Add to watchlist
children
Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis
Published: 2023-03-18 (Crawled : 16:20) - globenewswire.com
SNY | News | $46.135 1.64% 270K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 600K
|
Health Technology
| Email alert
Add to watchlist
REGN | $901.745 0.87% 87K
|
Health Technology
| Email alert
Add to watchlist
dupixent dermatitis show
Press Release: Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis
Published: 2023-03-18 (Crawled : 16:20) - globenewswire.com
SNY | News | $46.135 1.64% 270K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 600K
|
Health Technology
| Email alert
Add to watchlist
REGN | $901.745 0.87% 87K
|
Health Technology
| Email alert
Add to watchlist
dupixent dermatitis show
Global Immunotherapy Drugs Market Report to 2028 - Players Include F. Hoffmann-La Roche, GSK, Merck & Co, Pfizer and Sanofi
Published: 2023-02-11 (Crawled : 16:20) - prnewswire.com
AZN | $68.505 0.21% 580K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.135 1.64% 270K
|
Health Technology
| Email alert
Add to watchlist
AZNCF | $138.24 -1.36% 0
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 600K
|
Health Technology
| Email alert
Add to watchlist
BMY | $48.295 -0.01% 920K
|
Health Technology
| Email alert
Add to watchlist
global immunotherapy report sanofi market
Global Infantry Fighting Vehicle Industry Report 2022: Upgrades of Existing Structure and Growing Popularity of Unmanned Combat Vehicles is Expected to Boost Demand
Published: 2023-02-11 (Crawled : 16:20) - prnewswire.com
GD | $288.11 1.0% 100K
|
Electronic Technology
| Email alert
Add to watchlist
SNY | News | $46.135 1.64% 270K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 600K
|
Health Technology
| Email alert
Add to watchlist
global vehicles report growing expected
Global Military Truck Market Report 2022-2027: Launch of Customized Trucks Bodes Well for the Sector
Published: 2023-02-11 (Crawled : 16:20) - prnewswire.com
TXT | $93.5 0.99% 85K
|
Electronic Technology
| Email alert
Add to watchlist
SNY | News | $46.135 1.64% 270K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 600K
|
Health Technology
| Email alert
Add to watchlist
OSK 4 | $117.765 0.09% 26K
|
Producer Manufacturing
| Email alert
Add to watchlist
global truck trucks report military market
Health Equity Report Card Pilot Project to Help Close the Care Gap Highlighted on World Cancer Day
Published: 2023-02-04 (Crawled : 16:20) - prnewswire.com
SNY | News | $46.135 1.64% 270K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 600K
|
Health Technology
| Email alert
Add to watchlist
ABBV | News | $165.09 0.26% 760K
|
Health Technology
| Email alert
Add to watchlist
day care report health pilot cancer
Pivotal Odronextamab (CD20xCD3) Phase 2 Data in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Debut at ASH
Published: 2022-12-11 (Crawled : 16:20) - prnewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.135 1.64% 270K
|
Health Technology
| Email alert
Add to watchlist
REGN | $901.745 0.87% 87K
|
Health Technology
| Email alert
Add to watchlist
cd20 phase 2
IGM Biosciences Presents Data from T cell Engager Portfolio for Hematologic Malignancies at 2022 American Society of Hematology Annual Meeting
Published: 2022-12-11 (Crawled : 16:20) - globenewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.135 1.64% 270K
|
Health Technology
| Email alert
Add to watchlist
IGMS | $7.205 -2.77% 22K
|
Health Technology
| Email alert
Add to watchlist
meeting
Global Times: 5 years on, CIIE reaffirms China's determination for high-level opening-up, brings confidence to the world
Published: 2022-11-06 (Crawled : 16:20) - prnewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.135 1.64% 270K
|
Health Technology
| Email alert
Add to watchlist
global
Press Release: Pivotal data demonstrate once-weekly efanesoctocog alfa provides superior bleed protection compared to prior factor prophylaxis
Published: 2022-07-10 (Crawled : 16:20) - globenewswire.com
SNY | News | $46.135 1.64% 270K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 600K
|
Health Technology
| Email alert
Add to watchlist
Gainers vs Losers
| 82% | 18% |
Top 10 Gainers
AGBA | News | $1.37 242.5% 76M
|
Finance
EGOX | $0.0835 131.94% 160M
|
ZCMD | $2.18 50.35% 24M
|
Commercial Services
CHRO | $1.73 41.22% 46K
|
n/a
RWOD | $10.61 32.68% 5.1M
|
n/a
NVFY | $2.77 31.28% 2.2M
|
Consumer Durables
AULT | $0.3174 31.1% 28M
|
Manufacturing
WISA 4 | $7.11 20.71% 4.7M
|
Electronic Technology
LIFW | News | $0.99 19.26% 800K
|
Administrative and Support and ...
PRTG | $0.285 18.75% 140K
|
Mining, Quarrying, and Oil and ...
Your saved searches
Save your searches and get alerts when important news are released.